ProCE Banner Activity

CLL Management: Testing for MRD and BTK Mutations

Clinical Thought

In this commentary, an expert discusses the usefulness and implications of routine testing for minimal residual disease and BTK mutations in the management of chronic lymphocytic leukemia and why understanding BTK inhibitor resistance is critical for improving patient care.

Released: November 05, 2024

Expiration: November 04, 2025

Share

Faculty

Jennifer R. Brown

Jennifer R. Brown, MD, PhD

Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
CLL Center Director and Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca

Disclosure

Primary Author

Jennifer R. Brown, MD, PhD

Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
CLL Center Director and Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Jennifer R. Brown, MD, PhD: consultant/advisor/speaker: AbbVie, Acerta/AstraZeneca, Alloplex Biotherapeutics, BeiGene, Bristol Myers Squibb, EcoR1, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare, Kite, Loxo/Lilly, Magnet Biomedicine, Merck, Numab, Pharmacyclics; researcher: BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, TG Therapeutics; data and safety monitoring board: Grifols Therapeutics.